These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33285037)

  • 1. Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study.
    Komaki H; Takeshima Y; Matsumura T; Ozasa S; Funato M; Takeshita E; Iwata Y; Yajima H; Egawa Y; Toramoto T; Tajima M; Takeda S
    Ann Clin Transl Neurol; 2020 Dec; 7(12):2393-2408. PubMed ID: 33285037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
    JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; McDonald CM; Smith EC; Zaidman CM; Nakagawa T; ; Hoffman EP
    J Neuromuscul Dis; 2022; 9(4):493-501. PubMed ID: 35634851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; McDonald CM; Smith EC; Zaidman CM; Nakagawa T; ; Hoffman EP
    J Neuromuscul Dis; 2023; 10(3):439-447. PubMed ID: 37005891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
    Cirak S; Arechavala-Gomeza V; Guglieri M; Feng L; Torelli S; Anthony K; Abbs S; Garralda ME; Bourke J; Wells DJ; Dickson G; Wood MJ; Wilton SD; Straub V; Kole R; Shrewsbury SB; Sewry C; Morgan JE; Bushby K; Muntoni F
    Lancet; 2011 Aug; 378(9791):595-605. PubMed ID: 21784508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapy.
    Czifrus E; Berlau DJ
    Expert Rev Neurother; 2023; 23(10):853-858. PubMed ID: 37572081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy.
    Vincik LY; Dautel AD; Staples AA; Lauck LV; Armstrong CJ; Howard JT; McGregor D; Ahmadzadeh S; Shekoohi S; Kaye AD
    Adv Ther; 2024 Apr; 41(4):1338-1350. PubMed ID: 38376743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viltolarsen: First Approval.
    Dhillon S
    Drugs; 2020 Jul; 80(10):1027-1031. PubMed ID: 32519222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.
    Kinali M; Arechavala-Gomeza V; Feng L; Cirak S; Hunt D; Adkin C; Guglieri M; Ashton E; Abbs S; Nihoyannopoulos P; Garralda ME; Rutherford M; McCulley C; Popplewell L; Graham IR; Dickson G; Wood MJ; Wells DJ; Wilton SD; Kole R; Straub V; Bushby K; Sewry C; Morgan JE; Muntoni F
    Lancet Neurol; 2009 Oct; 8(10):918-28. PubMed ID: 19713152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
    Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
    Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial.
    Wagner KR; Kuntz NL; Koenig E; East L; Upadhyay S; Han B; Shieh PB
    Muscle Nerve; 2021 Sep; 64(3):285-292. PubMed ID: 34105177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
    Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G
    PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viltolarsen for the treatment of Duchenne muscular dystrophy.
    Roshmi RR; Yokota T
    Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
    Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M
    Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.
    Anthony K; Cirak S; Torelli S; Tasca G; Feng L; Arechavala-Gomeza V; Armaroli A; Guglieri M; Straathof CS; Verschuuren JJ; Aartsma-Rus A; Helderman-van den Enden P; Bushby K; Straub V; Sewry C; Ferlini A; Ricci E; Morgan JE; Muntoni F
    Brain; 2011 Dec; 134(Pt 12):3547-59. PubMed ID: 22102647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.
    Frank DE; Schnell FJ; Akana C; El-Husayni SH; Desjardins CA; Morgan J; Charleston JS; Sardone V; Domingos J; Dickson G; Straub V; Guglieri M; Mercuri E; Servais L; Muntoni F;
    Neurology; 2020 May; 94(21):e2270-e2282. PubMed ID: 32139505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
    JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies.
    Sheikh O; Yokota T
    Expert Opin Investig Drugs; 2021 Feb; 30(2):167-176. PubMed ID: 33393390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.